… concentration was above 100 μmol/m 2 (83%), with a significant decrease where the maximum
concentration was between 50 and 100 μmol/m 2 (15.5%), and below 50 μmol/m 2 (1.5%)…

Acute and diffuse contamination of soil by organic and inorganic pollutants causes wide
concerns and intentional or accidental introduction of these substances poses serious impact in …

Over the past years, mucosal healing has emerged as a major therapeutic goal in clinical
trials in inflammatory bowel diseases. Accumulating evidence indicates that mucosal healing …

BACKGROUND & AIMS: We previously established long-term culture conditions under which
single crypts or stem cells derived from mouse small intestine expand over long periods. …

… Marc Ferrante1, … (Biosentec, Toulouse, France); 250 mg feces were 2× diluted in
triethanolamine buffer (0.1 M, pH 9.15). Samples were centrifuged at 13 000 g for 5 min at 4C. The …

Background Complex perianal fistulas in Crohn's disease are challenging to treat. Allogeneic,
expanded, adipose-derived stem cells (Cx601) are a promising new therapeutic approach…

Endoscopy plays an essential role in the diagnosis, management, prognosis, and surveillance
of inflammatory bowel disease (IBD), but surprisingly there are few available guidelines. 1…

… Marc Ferrante took part in the statistical analysis and writing of the article. Severine
Vermeire took part in data analysis and writing of the article. Filip Baert took part in patient …

Background Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's
disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still …

Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating
patients with Crohn’s disease (CD) and ulcerative colitis (UC). We aimed to determine whether …